Incyte rises as it settles Medicaid dispute with US government

Incyte

22/06/2026 12:25

** Shares of drugmaker Incyte INCY.O rise 2% to $100 premarket
** Says it settled dispute with U.S. government over Medicaid rebates tied to Opzelura, co's skin cream for inflammatory conditions
** Co says authorities will not treat Opzelura as linked to blood disorder drug Jakafi, avoiding higher rebate payments
** Says to record one-time, non-cash gain of about $246 mln in Q2 from reversing earlier charges
** Expects improved profit margins for Opzelura going forward
** Says to update financial outlook at next earnings release
** As of last close, stock up ~83% YTD
 
  

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))